• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Capitol Hill

Trump presses pharma execs on pricing, U.S. production

January 31, 2017 By Sarah Faulkner

Capitol Hill

Executives from pharmaceutical companies including Johnson & Johnson (NYSE:JNJ), Amgen (NSDQ:AMGN), Merck (NYSE:MRK) and Eli Lilly (NYSE:LLY) met with President Donald Trump today to discuss issues ranging from drug pricing to regulatory approval for pharmaceuticals. The president called on the company execs to increase U.S. production and lower “astronomical” drug prices. Although Trump doubled down on his […]

Filed Under: Policy, Wall Street Beat Tagged With: Amgen, Capitol Hill, Eli Lilly & Co., johnsonandjohnson, Merck

Healthcare industry braces for change on Trump’s executive order

January 23, 2017 By Sarah Faulkner

Capitol Hill

President Donald Trump signed an executive order on Friday that could scale back enforcement of some provisions of the Affordable Care Act, also called Obamacare, and analysts warned that shares of hospitals and Medicaid providers could face new pressure as fears over losing coverage grow. President Trump wrote that government departments should “waive, defer, grant […]

Filed Under: Policy, Wall Street Beat Tagged With: Capitol Hill

Bipartisan report from senators calls for drug pricing reform

December 22, 2016 By Sarah Faulkner

Capitol Hill

The U.S. Senate Special Committee on Aging released a bipartisan report yesterday suggesting ways to respond to spikes in drug pricing. The report comes after a months-long investigation spearheaded by Sens. Susan Collins (R-Maine) and Claire McCaskill (D-Missouri). The senators wrote that massive spikes in drug prices are “gouging” patients and that lawmakers should respond. […]

Filed Under: Featured, Legal News, Pharmaceuticals, Policy Tagged With: Capitol Hill, Mylan, Teva Pharmaceuticals

21st Century Cures Act adds Hatch-Waxman rule to drug-device combos

December 20, 2016 By Sarah Faulkner

Capitol Hill

Section 3038 of the 21st Century Cures Act applies Hatch-Waxman rules to certain drug-device combination products, addressing the regulatory pathway for devices that incorporate already approved drugs. The Hatch-Waxman Act, named for Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.), was approved in 1984. It was designed to make it easier for generic drugs to enter […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Regulatory/Compliance Tagged With: Capitol Hill

Federal watchdog to investigate CMS drug rebate program

December 12, 2016 By Sarah Faulkner

Mylan

The Office of the Inspector General of the Health and Human Services Departments said last week that it will begin investigating whether the Centers for Medicare & Medicaid Services properly monitors its Medicaid Drug Rebate Program. The investigation comes after CMS reported that Mylan (NSDQ:MYL) underpaid Medicaid by not paying appropriate rebates. The Canonsburg, Penn.-based company said […]

Filed Under: Featured, Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Centers for Medicare and Medicaid Services (CMS), Mylan

Trump comments send pharma, biotech shares down

December 7, 2016 By Sarah Faulkner

Capitol Hill

(Reuters) – President-elect Donald Trump on Wednesday took aim at drugmakers, promising in a magazine interview that “I’m going to bring down drug prices,” and shares of U.S. pharmaceutical and biotechnology companies fell. In a cover story for Time magazine, which named him its Person of the Year, Trump said that “I don’t like what […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Biogen Idec, Capitol Hill, Pfizer Inc.

Committee pens letter to Mylan demanding EpiPen price info

October 4, 2016 By Sarah Faulkner

Mylan

Members of the U.S. House Committee on Oversight & Government Reform penned a letter to Mylan (NSDQ:MYL) demanding a more complete look at the pricing of its EpiPen epinephrine auto-injector. At a Sept. 21 congressional hearing, Mylan CEO Heather Bresch testified that the company makes a $100 profit per 2-pack of EpiPens. Last week, Mylan […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured Tagged With: Capitol Hill, Mylan

Mylan clarifies $104 profit on $600 EpiPens

September 27, 2016 By Sarah Faulkner

Mylan

Mylan (NSDQ:MYL) acknowledged that the $104 profit it reported to Congress included taxes, after the Wall Street Journal reported that the company applied the statutory U.S. tax rate of 37.5% to calculate its profits for testimony before the Senate, according to Reuters. “Without the tax-related reduction, Mylan’s profits on the EpiPen 2-pack would be closer […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Wall Street Beat Tagged With: Capitol Hill, Mylan

Senate panel to investigate Mylan’s EpiPen pricing

September 8, 2016 By Sarah Faulkner

The U.S. Senate’s investigations panel is reportedly launching a “preliminary inquiry” into Mylan’s (NSDQ:MYL) pricing of the EpiPen epinephrine auto-injector. Mylan came under fire in recent weeks for raising the price of EpiPens nearly 500%, from $100 in 2008 to more than $500 this year, despite stable manufacturing costs. In late August, Sens. Amy Klobuchar […]

Filed Under: Drug-Device Combinations, Wall Street Beat Tagged With: Capitol Hill, Mylan

Mylan cuts EpiPen price in half after criticism

August 25, 2016 By drugdelivery

By Sarah Faulkner Mylan (NSDQ:MYL) said today that it would reduce the out-of-pocket patient cost for its EpiPen product, after being widely criticized for raising the price nearly 500% since 2009. Although the list price for the epinephrine injector remains the same, Mylan said it would increase eligibility for its patient assistance program, which eliminates out-of-pocket costs for uninsured […]

Filed Under: Drug-Device Combinations, Wall Street Beat Tagged With: Capitol Hill, Mylan

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS